|
Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse
|
Jul 2020
|
Blood Advances
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure
|
Jul 2020
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
|
Jul 2020
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Targeting the Microenvironment in MDS: The Final Frontier
|
Jul 2020
|
Frontiers in Pharmacology
|
myelodysplastic syndromes (MDS)
|
|
Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International PNH Registry
|
Jul 2020
|
European Journal of Haematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Kinetics of Pre-Myelodysplastic Syndromes Blood Values Correlate with Disease Risk and Survival
|
Jul 2020
|
Hematological Oncology
|
myelodysplastic syndromes (MDS)
|
|
High-dose Romiplostim Accelerates Hematologic Recovery in Patients With Aplastic Anemia Refractory to Eltrombopag
|
Jul 2020
|
Leukemia
|
aplastic anemia
|
|
Genetics of Progression From MDS to Secondary Leukemia
|
Jul 2020
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
|
Jul 2020
|
Blood
|
aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Where There's Smoke, There's Fire: Inflammation Drives MDS
|
Jul 2020
|
Trends in immunology
|
myelodysplastic syndromes (MDS)
|
